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Cholinergic neuromodulation is involved in all aspects of sensory
processing and is crucial for processes such as attention, learning
and memory, etc. However, despite the known roles of acetylcho-
line (ACh), we still do not how to disentangle ACh contributions
from sensory or task-evoked changes in functional magnetic
resonance imaging (fMRI). Here, we investigated the effects of
local injection of ACh on fMRI and neural signals in the primary
visual cortex (V1) of anesthetized macaques by combining
pharmaco-based MRI (phMRI) with electrophysiological record-
ings, using single electrodes and electrode arrays. We found that
local injection of ACh elicited two distinct profiles of fMRI and
neurophysiological activity, depending on the distance from the
injector. Near the injection site, we observed an increase in the
baseline blood oxygen-level-dependent (BOLD) and cerebral blood
flow (CBF) responses, while their visual modulation decreased. In
contrast, further from the injection site, we observed an increase
in the visually induced BOLD and CBF modulation without changes
in baseline. Neurophysiological recordings suggest that the spatial
correspondence between fMRI responses and neural activity does
not change in the gamma, high-gamma, and multiunit activity
(MUA) bands. The results near the injection site suggest increased
inhibitory drive and decreased metabolism, contrasting to the far
region. These changes are thought to reflect the kinetics of ACh
and its metabolism to choline.
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The interpretation of functional magnetic resonance imaging(fMRI) studies requires understanding the quantitative re-
lationship between the blood oxygen-level-dependent (BOLD)
signal changes and their underlying electrophysiological activity.
Several studies have focused on understanding the nature of
electrophysiological signals [spikes vs. local field potentials
(LFPs)] driving the fMRI signal and have confirmed that fMRI
responses are generally reliable indicators of neural activity (1–
5). However, it has also been shown that the relation between
neural activity and fMRI responses can change in different
cognitive states (6, 7). These cognitive states are mediated by
diverse neuromodulators that enable transitions from one brain
state to another on a variety of time scales (8, 9). Neuro-
modulators can change the input–output relationship of neural
circuits, either locally or on a global scale, and adjust their energy
expenditure, and thereby they also affect the hemodynamic re-
sponses and fMRI signals (2, 8, 10, 11). However, it is unclear
how to interpret the effects of neuromodulation in fMRI signals,
for instance, how to disentangle the BOLD signal changes relating
to task or attention (presumably under neuromodulatory influ-
ence; ref. 12) from stimulus-driven or perceptual effects. Under-
standing how neuromodulators affect the BOLD responses is
essential for the effective interpretation of fMRI data, not only in
tasks involving attentional processes, but also for potential diag-
nostic use of fMRI, since many neurological and psychiatric dis-
orders lead to alterations in neuromodulatory systems (13).
Acetylcholine (ACh) is a key neuromodulator in the brain and
is involved in many aspects of cognition, including sensory pro-
cessing (14–16), attention (14), and learning and memory (17).
Nearly all cortical regions receive cholinergic projections that
originate from the basal forebrain (BFB; ref. 18), and histolog-
ical evidence has shown differential distributions of cholinergic
receptors (AChRs; refs. 19, 20) and acetylcholinesterase (AChE)
in cortex (21). However, despite this anatomical evidence, it has
generally been assumed that the cholinergic system exerts uni-
form effects across all cortical structures (22).
Studies using electrical microstimulation of BFB neurons (16,
22) and systemic injection of cholinergic agonists (23) have
shown increases in sensory-evoked neural activity in visual cortex
as well as in cerebral blood flow (CBF; refs. 22–25). This effect of
ACh has also been observed in other sensory modalities, such as
the somatosensory (26) and the auditory cortices (27). However,
it is unclear to what extent these changes are the result from
local cholinergic effects or caused by a chain of events in-
stantiated by global changes in ACh levels (28).
In this study, we combined intracortical injections of ACh with
pharmaco-MRI (BOLD and CBF) and electrophysiology [single-
electrode physiology and microelectrocorticography (μECoG)
electrode arrays] to investigate the impact of cholinergic neu-
romodulation on neural responses and neurovascular coupling
in macaque V1. Applying ACh in anesthetized animals allowed
us to investigate the mechanisms by which ACh affects neural
and fMRI responses without the potentially confusing effects of
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behavioral processes like attention (15) or learning (29). We
found two distinct cholinergically induced effects in the fMRI
and neurophysiological responses in V1. Near the injection site,
the amplitude of the BOLD, CBF, and neural responses to the
visual stimulus was decreased and the baseline increased. Fur-
ther away from the injection site, visually induced modulation of
the BOLD, CBF, and neural responses increased, with no
changes in the baseline, and preserved neurovascular coupling.
Results
Our goal was to investigate the effects of cholinergic neuro-
modulation on neurovascular coupling. For this, we combined
functional imaging in V1 with neurophysiology and pharmacol-
ogy in anesthetized nonhuman primates (Macaca mulatta). We
acquired BOLD, functional CBF (fCBF), and neurophysiological
data, the latter using single electrodes as well as μECoG arrays,
while animals viewed a rotating checkerboard (Fig. 1 A and B).
We mimicked cholinergic neuromodulation by locally applying
ACh in V1. To ensure that ACh was reliably delivered, we
monitored the changes in the concentration of ACh in the ex-
tracellular space using microsampling in conjunction with HPLC
coupled to mass spectrometry (SI Appendix, Fig. S1). Following
the injection of ACh, we found that levels of ACh immediately
increased from baseline levels and returned to baseline levels
10 min after the end of the injection (SI Appendix, Fig. S1B).
ACh Alters Sensory Evoked Neural Activity in Primary Visual Cortex.
We first investigated the effects of ACh on neural activity, be-
cause studies have shown that at the neural population level,
ACh reduces excitability (30–33). We were interested to know if
our pharmacological approach yielded similar results to those
reported. We used neurophysiology data that was simultaneously
collected with fMRI data and calculated the absolute power
spectral density (PSD) from the LFPs and multiunit activity
(MUA) using previously described methods (11, 34). Changes in
the PSD are good indicators of changes in neural activity, as
these reflect changes in the coordinated activity of excitatory and
inhibitory postsynaptic potentials (1, 3, 5, 35, 36). Our analysis
revealed that injection of ACh decreased the power of the
neuronal activity across a wide frequency range (1–250 Hz; SI
Appendix, Fig. S2). However, given that it has been shown that
the gamma (γ; 50–90 Hz), high-gamma (hγ; 91–150 Hz), and MUA
(900–3,000 Hz) bands carry most information about the sensory
stimulus and are most strongly correlated with the fMRI signal (4, 5,
37), we focused our analysis on these bands.
Fig. 2 illustrates the effects of ACh injection on the LFP and
MUA: Fig. 2 A–C show the average time courses over 15 ex-
perimental sessions for the extracted frequency bands. The visual
stimulus caused an increase in power/amplitude of >10% com-
pared with baseline in all frequency bands. A substantial effect of
the ACh injection is evident in the γ, hγ, and MUA bands (Fig. 2
A–D) as a decrease in visual modulation in the γ (MODdrug, γ
62 ± 2%; P = 0.028), in the hγ (MODdrug, hγ 65 ± 2%; P = 0.031),
and in the MUA (MOD drug, mua 64 ± 1%; P = 0.025) bands. The
effects of ACh on the γ, hγ, and MUA amplitude returned to
baseline ∼22 min after the ACh infusion was stopped.
Moreover, it has been shown that ACh can affect the ampli-
tude of the response as well as the variability of the neural ac-
tivity, which impacts the information encoding in the visual
cortex (8, 9, 15, 16, 38). Therefore, we calculated the signal-to-
noise ratio (SNR). This showed an increase in SNR in the hγ
(SNR drug, hγ = 11.5 ± 2.4 dB; P = 0.031, paired t test) and MUA
(SNR drug, MUA = 11 ± 2.2 dB; P = 0.027, paired t test) bands
starting shortly after the beginning of the injection. The SNR in
the γ band was not significantly increased (SNR drug, γ = 10.4 ±
2.8 dB; P = 0.59, paired t test). None of these effects were ob-
served during control injection of artificial cerebrospinal fluid
(ACSF; see SI Appendix, Figs. S2 and S3).
Evoked BOLD Responses Under Cholinergic Influence. The neural
data in Fig. 2 were recorded simultaneously with BOLD re-
sponses. Fig. 3A shows an example of a typical functional acti-
vation map showing the selected V1 regions before and during
injection of ACh. We selected two regions of interest (ROIs)
(Fig. 1C) according to their location relative to the injector:
ROINEAR (voxels located within a ∼2-mm diameter surrounding
the electrode) and ROIFAR (voxels located further away from the
injector, 3–5 mm). These criteria led us to identify two distinct
effects of ACh in the BOLD signal. The average visually induced
BOLD change in V1 was 5.8 ± 0.25% (15 experimental sessions)
in both ROIs. The activated voxels in both selected regions are
color-coded according to their percentage changes (Fig. 3A) and
location in the near or far ROI. Fig. 3 B and C show the time
courses of the response of the BOLD modulation over the
course of the ACh injection in both ROIs. The time course for
the voxels in the ROINEAR (BOLDNEAR; red) exhibited an in-
crease in the baseline following the start of the injection, which
reached its maximum ∼2 min after the start of the injection (Fig.
3B). In contrast, the time course of the ROIFAR (Fig. 3C,
BOLDFAR) did not show this shift in the baseline and remained
stable throughout the experiment. ACh also elicited different
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Fig. 1. Experimental paradigm and representative example of an experi-
mental session showing functional activation maps for BOLD and CBF. (A)
Experimental paradigm and design. The stimulus paradigm consisted of
blocks of a rotating polar black-and-white checkerboard of 32 s intervened
by a black screen of equal duration. (B) Every experiment was divided in two
sessions: an 8-min scan without pharmacological intervention to define the
ROIs (B1); and a longer scan consisting of 37 stimulus repetitions during
which local cholinergic injection took place (B2). The start of the injection
was at 4 min (fourth repetition), and the injection finished at 8.5 min (end of
eighth repetition). (C) Functional activation maps of voxels that showed a
significant response to the visual stimulus. C, Upper represents the activation
in V1 (E04.S91). (C, Left Upper) Activation map for BOLD: FOV 6.4 × 4.8 mm2.
(C, Center Upper) CBF, FOV, 64 × 64 mm2. (C, Left and Center Lower) The
BOLD and CBF time courses of the activation in two ROIs: These two ROIs
were defined based on the location of the injector (blue arrow): Near cor-
responds to voxels near the injector (red arrow), and Far corresponds to
voxels far from the injection site (3–5 mm, green arrow).
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effects on the visually induced modulation in the “near” and
“far” regions. The visual modulation in the BOLDNEAR de-
creased, while the BOLDFAR modulation increased (Fig. 3 B and
C, respectively). To quantify the effects of ACh on the evoked
BOLD responses, we analyzed the modulation in response to
visual stimulation normalized to the predrug condition (Fig. 3 D
and E). During the drug infusion, the mean BOLDNEAR exhibi-
ted a significant reduction in the modulation compared with the
predrug condition (MODdrug, NEAR 48 ± 3%; P = 0.032, paired
t test; Fig. 3D, shown in red). In contrast, the mean BOLDFAR
showed a significant increase in the amplitude of visually evoked
responses (MODdrug, FAR 133 ± 4%; P = 0.036, paired t test; Fig.
3D, shown in teal). To get a better intuition about the effects
elicited by the ACh injection, we also computed baseline changes—
that is, the image intensity in the periods without visual stimulation
(Fig. 3E). We found that mean BOLDNEAR exhibited a substantial
increase in its baseline (BOLDdrug, NEAR 136 ± 3%; P = 0.025,
paired t test), while the baseline did not change for BOLDFAR.
None of these changes were observed during control injections of
ACSF (SI Appendix, Fig. S3).
Evoked CBF Responses Under Cholinergic Influence. The BOLD
signal reflects the deoxyhemoglobin concentration [dHb] and
thus is affected by changes in the cerebral blood volume (CBV),
CBF, and cerebral metabolic rate of oxygen consumption
(CMRO2). In earlier work, we showed that these fMRI signals
were differentially affected by dopamine (10) and found that
BOLD-fMRI alone cannot be used to make inferences about
changes in neural activity and metabolism under neuromodulation.
Following this line of argument, we performed CBF measure-
ments using the same pharmacological approach. Using arterial
spin labeling (ASL) in combination with BOLD-fMRI and elec-
trophysiology may offer better insights into the changes in energy
metabolism following changes in neural activity. Fig. 4A shows
activation patterns of the CBF in V1 before and during injection
of ACh. As for the BOLD responses, we generated two ROIs
relative to the location of the injector and computed the visually
induced modulation and baseline changes. The mean CBF change
in the ROIs was 36 ± 2.1% (seven experimental sessions), in line
with earlier CBF changes in anesthetized monkeys V1 (39–41).
The average time course of the CBFNEAR across experiments (Fig.
4B) showed a positive shift in the baseline and a decrease in vi-
sually induced modulation similar to the changes in the BOLD
activity. When comparing the CBFNEAR “predrug” period with the
“drug” period, we observed a mean decrease in the visually in-
duced modulation (CBFdrug, NEAR = 65 ± 5%; P = 0.043, paired
t test, n = 7). The largest CBF decrease was observed toward the
end of the infusion (62% at ∼8 min after the start of the infusion;
Fig. 4D). The increase in the baseline started ∼1.5 min after the
onset of the injection (CBFdrug, NEAR = 118 ± 4%; P = 0.038,
paired t test). In contrast, the CBFFAR showed a mean increase in
the visually induced modulation (CBFdrug, FAR = 123 ± 5%; P =
0.042, paired t test) and no changes in the baseline (Fig. 4 D and
E), similar to those reported for BOLD. To summarize, the CBF
experiments also revealed two distinct changes in the CBF responses
and mirrored the BOLD and neural responses. An increase of the
baseline and a decrease in visually evoked modulation was observed
in the CBFNEAR, whereas we observed an increase in the visually
induced modulation and no changes in the baseline for CBFFAR.
ACh Does Not Change the Correspondence Between Neural Activity
and fMRI Responses. An important question was to establish
whether the two distinct cholinergically induced profiles of fMRI
activity, in the different spatial regions, corresponded with the
local neural activity. To record neural responses over an area
corresponding to the extent of the fMRI responses, we acutely
implanted μECoG arrays on the surface of the brain (Fig. 5A,
μECoG 32 channels). We selected the electrode contacts
according to the following criteria: (i) electrodes that were lo-
cated within a 1-mm ratio close to the injector were assigned as
ECoGNEAR (Fig. 5A, shown in red); (ii) electrodes that were
within a ratio of 1.5–2.5 mm were assigned as ECoGFAR (Fig. 5A,
shown in teal); and (iii) electrodes that were located on top of a
blood vessel were not considered in the analysis. We first de-
termined if there were differences between the LFP power in the
two regions by computing the strength of the oscillatory activity
across electrodes in ECoGNEAR and ECoGFAR. Fig. 5B denotes a
typical average LFP spectrum in V1 over electrode sites located
in ECoGNEAR (six experimental sessions) and electrode sites in
ECoGFAR, shown in red and teal, respectively. Similar to what we
observed during single-electrode recordings, the broadband LFP
power in the near region decreased following the injection of
ACh (SI Appendix, Fig. S2, shown in red). Moreover, the power
in the broadband LFP in the region far from the injector in-
creased (SI Appendix, Fig. S2, shown in blue).
Fig. 5 C–F illustrates the effects of ACh on the γ LFP bands:
Fig. 5 C and D shows the average time courses across experi-
ments for the γ and hγ. We focused on the γ and hγ, given that
these bands originate from different sources. For instance, γ is
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Fig. 2. Local application of ACh decreases the power in LFP and MUA
bands. The average time course of the neural activity (γ, hγ, and MUA bands)
across experiments in response to ACh injection (n = 15 sessions) is shown.
The green and red arrows indicate the beginning and end of the injection of
ACh (shaded gray area). (A) The γ band (50–90 Hz). (B) The hγ band (91–150 Hz).
(C) MUA band (900–3,000 Hz). In all bands, the amplitude of the visual re-
sponse decreased following the injection of ACh, while the variability de-
creased in the hγ and MUA bands, but not in the γ band. (D) Percentage
changes in visual response of γ, hγ, and MUA. (E) The SNR of the hγ and MUA
increases upon ACh infusion, as a result of decreased variability.
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closely linked to changes in excitation/inhibition balance, while
the hγ has a closer relation to the MUA (42, 43). The average
visually induced modulation in the γ range was increased >13%
relative to the baseline. The effects of ACh on activity recorded
by electrodes in ECoGNEAR were similar to the effects described
in Fig. 2—that is, we observed that during the injection period,
the visual modulation in the γ band decreased (MODγ, NEAR 63 ±
3%; P = 0.031; Fig. 5 C and E, dark red), as well as in the hγ
band (MODhγ, NEAR 72 ± 4%; P = 0.038; Fig. 5 C and E, red). In
contrast, the electrodes located in ECoGFAR showed an increase
in the amplitude of the γ band during the injection period
(MODγ, FAR 123 ± 2%; P = 0.033; Fig. 5 D and E, blue) and hγ
band (MODhγ, FAR 124 ± 2%; P = 0.038; Fig. 5 D and E, teal).
The SNR in the γ range at the ECoGNEAR electrodes was un-
affected by the ACh injection (SNRγ, NEAR = 0.95 ± 0.15 dB; P =
0.38; Fig. 5F, dark red). However, the SNR in the hγ range in-
creased (SNRhγ, NEAR = 1.14 ± 0.18 dB; P = 0.033; Fig. 5F, light
red). The SNR of the γ band recorded by electrodes in the
ECoGFAR region was unaffected by the injection (SNRγ, FAR =
0.98 ± 0.25 dB; P = 0.33 paired t test; Fig. 5F, dark blue), while
the SNR in the hγ showed a decrease (SNRhγ, FAR = 0.83 ±
0.35 dB; P = 0.031 paired t test; Fig. 5F, green). Overall, these
results reveal (i) a reduced neural activity at the population level
(γ) in the region near the injector while neural activity was in-
creased far from the injector; and (ii) a direct cholinergic in-
fluence in shaping the fidelity (SNR) of neural γ activity in the
region near the injector, while fidelity appears to decrease away
from the injector.
ACh Pharmacodynamics. The profiles of fMRI and neurophysio-
logical activity described above can be caused by the effects of
ACh or could be due to the influence of choline (Ch). Ch is the
immediate metabolite of ACh and has been shown to activate
nAChRs and to increase neural activity (44, 45). By extracting
extracellular brain fluid (EBF) using microdialysis (see detailed
information in SI Appendix; ref. 46), we simultaneously moni-
tored how our injections influenced the concentration of Ch and
ACh in the EBF in V1. We found that, following the ACh in-
jection, the concentrations of ACh and Ch increased (SI Ap-
pendix, Fig. S1B, shown in blue and red, respectively). However,
ACh and Ch exhibited different pharmacodynamics (for details,
see SI Appendix, Fig. S1B).
Discussion
We used pharmaco-MRI (BOLD and CBF), neurophysiology
(single-electrode recording and μECoG arrays), and intracortical
injections to understand the effects of ACh on neural and fMRI
activity in V1. The main finding is that the injection of ACh
elicits two distinct fMRI and neural responses in V1 depending
on the distance to the injector: (i) near the injection site, the
stimulus-induced fMRI responses (BOLD and CBF) decreased
with a concomitant increase in baseline activity, while the power
of the neural activity decreased and its SNR increased; and (ii)
further away from the injector we observed an increase in the
visually induced modulation of the hemodynamic signals with a
concomitant increase in LFP power but a decrease in the SNR of
the neural activity. The decreased cell-population activity con-
comitant with the BOLD and CBF responses in the region near
the injector might be an indication of decreased energy de-
mands, while further away from the injector, the increased
neural activity and fMRI responses might suggest increased en-
ergy demands. The increases in modulation of the hemodynamic
and neural responses in the region far from the injector suggest
an increased metabolic demand due to the increased neural
activity, which might be due to the activation of nAChRs caused
by Ch. Overall, our findings indicate that the effects of neuro-
modulators can vary considerably, depending on properties of
local circuits and neuromodulators, such as the distance from
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Fig. 3. ACh elicits distinct BOLD effects in regions near
to and far from the injector. Mean effects of ACh in-
jection are shown. (A) Activation maps of voxels
responding to visual stimulation and time courses
showing BOLD responses before and during the in-
jection of ACh [monkey B05; gradient-echo (GE) echo-
planar imaging (EPI) with 1-mm slice thickness]. (B) Time
course of BOLDNEAR (red) response in 15 fMRI experi-
mental sessions showed a decrease in visually induced
modulation and a baseline increase following injection.
(C) The time course of the BOLDFAR (green) response
showed an increase in visually induced modulation
without a baseline shift. (D) The average BOLDNEAR re-
sponse to the visual stimulus decreased by 45% com-
pared with the predrug period, while it increased by
43% for the BOLDFAR. The arrows indicate the time at
which the effect begins following the start of the in-
jection. (E) The baseline did not change in the far re-
gion, but it increased in the near region.
E12076 | www.pnas.org/cgi/doi/10.1073/pnas.1808507115 Zaldivar et al.
release of a neuromodulator, concentration differences, and the
kinetics of the neuromodulator.
Cholinergically Induced Changes in Neural Activity. ACh decreased
the power in the γ, hγ, and MUA bands near the injection site.
This decrease in power is in good agreement with electrophysio-
logical studies in monkeys, which demonstrated strong inhibition
of V1 activity after ACh injection (21, 32, 33). This has been as-
cribed to the activation of muscarinic receptors (mAChRs, par-
ticularly type 1), which are the most abundant AChRs in V1 (47)
and are mostly expressed on parvalbumin-immunoreactive (PV-ir)
interneurons (19, 31, 32), which in monkeys constitute 78% of the
interneurons in cortex (48).
Although our results are in good agreement with findings
reported in the sensory cortices of monkeys (32, 33), cats (49),
and guinea pigs (50), our results contrast with evidence showing
increased sensory-evoked activity in the sensory cortices of rats
(22, 51, 52). A possible explanation for this discrepancy may be
interspecies differences (33, 53). For instance, 25–95% of pyra-
midal neurons in the rodent sensory cortex are responsive to
ACh, leading to an increase in neural activity (53). This neuro-
modulatory effect is rare in monkeys because few excitatory
neurons express mAChR (19, 31). Moreover, in rat visual cor-
tex, <50% of inhibitory neurons are PV-ir (54), and they either
do not respond to (53) or are hyperpolarized by ACh (55).
The effects of ACh are multiple and complex and are ascribed
to various factors, including the concentration of ACh (17, 56),
the receptor types mediating cholinergic effects (15, 31, 32), and
density and location of cholinergic inputs and receptors (19). We
do not know for certain whether changes in network dynamics at
the injection site might lead to the changes observed in the far
region. Our neurophysiological recordings were collected si-
multaneously and from upper cortical layers, where the majority
of the output and lateral connections are located. However, we
believe that neural network effects are less likely to contribute to
the changes in the far region, because neurons in the near and
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Fig. 4. CBF responses elicited by local injection of ACh. (A) Activation maps of FCBF in primary visual cortex (monkey E04) in response to visual stimulation and
pharmacological injection. (B and C) Time course of the CBF response for the two ROIs (seven experimental sessions). (B) CBFNEAR shows an increase in the baseline
CBF and a decrease in visually induced CBF. (C) In contrast, the visually induced modulation in the CBFFAR increased, while the baseline did not change. (D) The
average visually induced modulation for CBFNEAR and CBFFAR showed a decrease (∼40%) and increase (∼20%), respectively, in response to ACh injection. (E) The
baseline CBFNEAR increased ∼30%, whereas the baseline CBFFAR did not show any changes following the injection.
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far region are driven by the same sensory stimulus—that is, a
full-field stimulus. The neuronal activity of nearby neurons
(within <2 mm) is usually synchronized, suggesting a prominent
contribution from horizontal cortical connections (57). However,
at larger distances, the correlation drops, reflecting a rapid
spatial decay of lateral connections (57, 58). Interestingly, in
vitro studies in cortical slice preparations have shown that ACh
suppresses the spread of cortical excitability within a distance
of <2 mm (59).
Cholinergic terminals in the cortex not only support wired
neurotransmission, but also volume transmission, suggesting that
ACh can influence an area beyond its site of release (60–63).
Therefore, the increase in LFP power further away from the
injector could be related to the diffusion of ACh from the site of
injection. However, concentration differences between both re-
gions cannot explain the distinct operational modes observed in
our results because lower concentrations of ACh in the far re-
gion relative to the site of the injection would have decreased
neural activity (29). In addition, the diffusion of ACh over a
larger area is usually limited by AChE, which is highly expressed
in cortex (21, 64). Thus, the most likely explanation of our results
in the region far from the injector is that these effects are me-
diated by the metabolites of ACh. ACh is metabolized into Ch
and acetate (65). Interestingly, studies have suggested that Ch ac-
tivates nicotinic receptors (nAChRs), particularly those expressing
the alpha-7 unit (44, 45, 66, 67). The activation of nAChRs is known
to increase neural activity as it enhances the thalamocortical post-
synaptic potentials (32, 51, 68), which in monkey V1 leads to an
A
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Fig. 5. The γ and hγ band activity in the near and far regions is differentially affected by ACh injection. (A) μECoG arrays used for this study consisted of
32 electrodes in a 4 × 8 pattern (small black dots) fabricated on a 20-μm-thick polyimide film. The arrays were positioned on the surface of the brain after
carefully opening the dura mater while avoiding damage to the surface of the brain. (B) LFP power spectrum from the near and far regions, during the
presentation of visual stimuli. (C and D) The average time course of neural activity across experiments in response to ACh injection (n = 6 experiments). The
green and red arrows indicate the start and end of the injection (indicated by the shaded area), respectively. (C) The γNEAR band (50–90 Hz; dark red) and
hγNEAR (91–150 Hz, red). (D) The γFAR band (blue) and hγFAR (green). (E) Percentage change in visual response for the γ frequency bands in the near and far
regions. The electrode sites near the injector showed a decrease in amplitude of the visually induced modulation, while the electrodes far from the injector
showed an increase in amplitude. (F) The SNR in the γ and hγ: The SNR for the near region increased in the γ and hγ bands, while the SNR in the far region
decreased, in particular in the hγ band.
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increase in responsiveness and contrast sensitivity of neurons
(32). In agreement with this hypothesis, our neurochemistry data
show a rapid decline of ACh compared with Ch, and given the
diffusion capabilities of Ch (69), we believe that the Ch-induced
activation of nAChRs in the far region is the most likely scenario.
However, further experiments are needed to better understand
these mechanisms.
Cholinergically Induced BOLD and CBF Profiles. Neuromodulators
affect the intrinsic dynamics of target neurons as well as the
metabolic properties of neural circuits (8, 10, 11, 22, 70), and, in
addition, they can have direct vascular effects. To better un-
derstand these different changes associated with ACh, we mea-
sured BOLD and fCBF, which reflect different aspects of the
hemodynamic response (71). The BOLD signal is driven by
changes in [dHb] and depends on the combined changes of CBF,
CBV, and the CMRO2. The CBF-based MRI signal reflects
protons in arterioles and capillaries and their exchange with
tissue water. In agreement with our neurophysiology results, we
found two distinct cholinergically induced profiles in the BOLD
and CBF responses, which depended on distance to the injection
site. Near the injector, we observed a decrease in the visually
evoked BOLD and CBF responses and an increase in the
baseline. The region further away from the injection site was
characterized by increased visually evoked BOLD and CBF re-
sponses, without affecting the baseline of fMRI signals. These
hemodynamic responses to visual modulation after ACh injection
qualitatively reflect the changes in neural activity, suggesting that
ACh and its metabolites do not cause large changes to the corre-
spondence between fMRI signals and the neurophysiological
responses.
The decrease in the stimulus-evoked BOLD and CBF responses
in the near region indicate that the [dHb] increased during the
ACh injection compared with the preinjection response. A de-
crease in BOLD and CBF modulation occur when the O2 con-
sumption stays the same or decreases by a smaller amount than
the reduction in inflow (72); the reduced neural activity suggests
that there is also a decrease in metabolic demand. The increases in
modulation of the hemodynamic and neural responses in the re-
gion far from the injector suggest an increased metabolic demand
due to the increased neural activity, which might be due to the
activation of nAChRs caused by Ch (45). The ACh- and Ch-
induced changes to BOLD, CBF, and neural activity are in the
same direction, suggesting qualitatively that neurovascular cou-
pling is preserved. Further studies are needed to determine
quantitative relationships between neural activity, BOLD, and
CBF and to determine the impact of ACh and Ch on the neural
population activity and fMRI responses in behaving animals.
The increase in the baseline of the BOLD and CBF near the
injector may be due to an increase in blood flow due to vaso-
dilation as a direct vascular effect of ACh (39, 71). Given that the
baseline neural activity did not change, such a vascular effect is
likely. Type 5 mAChRs are expressed on the surface of vessels in
rodents, and their activation was shown to increase blood flow (73,
74). However, it is still unclear whether this subclass of mAChRs is
also expressed on vessels in monkey or human cortex (75). An-
other possible explanation may be the increased concentration of
extracellular GABA resulting from the activation of mAChRs due
to the continuous infusion of ACh during the injection period (31,
33, 49). Although an increase in GABA would reduce neural ac-
tivity and thereby fMRI responses, the increased GABA can also
lead to enhanced production of nitric oxide and consequently
vasodilation (76). Indeed, this has been demonstrated in opto-
genetic studies where selective activation of PV-ir interneurons
caused vasodilation and increased the CBF (76–78). The absence
of changes to the baseline further away from the injector also
argues for a possible effect in this region of Ch, which is not known
to have direct effects on the vasculature. Further studies are
needed to elucidate the exact contributions of these mechanisms.
The reduction of stimulus-evoked neural activity, BOLD, and
CBF nearby the injector suggest a reduction of energy use after
stimulation as a result of the reduced neural activity. Similarly,
the increase in stimulus-induced BOLD, CBF, and neural activity
suggests an increase in energy use upon stimulation. Although these
are relative changes, CBF changes can be quantified in absolute
terms, and CMRO2 changes can be measured by using the cali-
brated BOLD method (79). Baseline values are less accessible with
the techniques we used and under this experimental paradigm.
Although BOLD fMRI is a relative metric, baseline CBF can be
quantified. What we called “baseline changes” here were the slow
(stimulus-independent) changes right after ACh injection. However,
it would be possible to measure the slow (resting-state) fluctuations
in neural activity, BOLD, and CBF in the presence and absence of
ACh, which could provide information about the nature of these
slow changes, their neural and vascular contributions, and their
relation to neuromodulation. However, this was beyond the scope
of this study, but would be interesting for further study.
Local and Global Cholinergic Influence. Much of what we know
about the impact of cholinergic neuromodulation on the fMRI
and neural activity has emerged from studies using electrical
stimulation of BFB or using pharmacology to systemically in-
crease the concentration of ACh (22, 23, 74, 80, 81). A systemic
increase in the level of ACh is known to up-regulate neural re-
sponses to stimuli in the somatosensory (26), auditory (27), and
visual cortices (16, 52, 81). However, whether the reported
changes are purely due to a cholinergic effect or due to the
generation of recurrent loops instantiated by the activation
AChRs in multiple brain areas is largely unknown.
The two profiles of fMRI and neural activity show that ACh
can act on local cortical circuits in V1, with responses varying
considerably depending on the features of the circuits. The dis-
tance from where the neuromodulator is released, its concen-
tration and kinetics (60), location (19, 20), distribution, and
density of AChRs (32, 33) are factors that play a role in ACh’s
effects and should be taken into account before inferences can
be made about cholinergic effects in cortical sensory areas.
Furthermore, similar aspects to those of cholinergic neuro-
modulation may also apply to other neuromodulators, given that
neuromodulators can mediate activity locally or through long-
range anatomical connections with other brain areas, or a com-
bination of both. Therefore, our findings highlight the impor-
tance of making a distinction between these mechanisms of
action to improve the interpretation of fMRI signals.
ACh Increases the SNR of Neural Responses. It has been shown that
stimulus encoding improves under influence of cholinergic neu-
romodulation (15, 38), and our results are in good agreement
with this idea, as we found an increase in SNR in the γ and MUA
bands near the injection site. This improved efficiency has been
linked to the activation of mAChRs expressed in the superficial
cortical layers (31, 32). ACh has also been shown to play an im-
portant role in gain modulation, as it is known to enhance the
activity from stronger inputs while decreasing the weaker inputs,
leading to an increase in SNR and promoting the readout of task-
related information (9, 15, 38). Our results show that far from the
injection site, the SNR decreases in both γ bands. This might be
due to the effects induced by the diffusion of Ch, given that it
activates α7-nAChRs, which is known to decrease disinhibition
(45, 82) and to increase neural activity at different rates (44, 67).
How this affects behavior needs to be tested in awake animals.
Limitations. A limitation of our study is that the combined elec-
trophysiology and BOLD data and the CBF and the ECoG data
were collected in different experimental sessions/animals. This
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was due to the technical difficulty of the experiments and the long
duration of the injection experiment. Hardware issues limited the
techniques that could be combined; for instance, the transmit
radiofrequency (RF) coil and phased array needed for CBF
measurement was not compatible with simultaneous electrophys-
iological recording, and the presence of electrodes reduces image
SNR and creates artifacts, precluding accurate CBFmeasurement.
Also, the ECoG grid was not compatible with simultaneous MRI.
Although average traces allow qualitative comparisons of neural
activity and BOLD and CBF data, the data do not support direct
quantitative comparison. The interindividual variation between
animals (83) also limits the quantitative inferences that can be
made, and further combined experiments would be needed to
address such questions.
Another possible limitation might be the layer specificity of our
neurophysiological recordings and pharmacological manipulations.
The injections and recordings performed by using the μECoG ar-
rays were confined to upper cortical layers, known to express
mAChRs and to most accurately encode visual information (41).
Although we cannot assign a specific laminar origin to the injection
and recording sites in the concurrent neurophysiology and fMRI
experiments, we believe that our recordings and injections were
mostly performed in superficial layers (e.g., II/III) based on the
following points: First, the electrode and the injector formed a
single unit and were inserted by using a microdrive that allowed us
to determine the depth of the electrode penetration. Additionally,
electrode insertion was done slowly under visual and auditory
guidance. The electrode has to traverse layers II/III, which are
layers with strong stimulus activity (84). Given the difficulty of our
experiments and the long duration of the injection trials, we usually
recorded from a single site (one electrode penetration) per day.
We recorded all experiments under general anesthesia, and we
do not foresee opportunities to perform similar manipulations in
alert monkeys in the near future. However, our anesthesia protocol
targets μ-opioid receptors which are highly expressed in basal
ganglia and thalamus, especially in regions related to motor func-
tion and pain, but regions associated with cognition (e.g., the ven-
tral tegmental area, substantia nigra, and frontal regions) have low
densities of μ-opioid receptors (85). A study from our laboratory
that compared results obtained in anesthetized monkeys with re-
sults from alert monkeys found that the neurovascular coupling was
relatively unaffected by this anesthesia protocol (1, 4), and a sub-
sequent study reported that the face-processing network was largely
unchanged under this anesthesia regimen (86). Therefore, it is
unlikely that the anesthesia regimen we used had a major influence
on the profiles of neural and hemodynamic responses reported
here. Anesthetized animals are, of course, not affected by changes
in behavioral state, and although this poses an advantage by
allowing us to assess effects of cholinergic neuromodulation with-
out the need to take behavioral parameters or the effect of other
neuromodulators into account, it is a limitation in the sense that it
does not allow us to relate our results directly to behavior.
Conclusions
Our results provide a comprehensive account of the effects of
locally applied ACh on neural and hemodynamic responses in
the macaque visual cortex. Our results show that local manipu-
lations of cholinergic neuromodulation elicit changes in neural
and fMRI activity that differ depending on the distance from the
injector and also from changes reported during systemic ma-
nipulation of ACh (22, 23, 74), where increases in fMRI and
neural responses were observed. This illustrates the difference
between local and global neuromodulatory effects of ACh on
neurovascular coupling and shows that it is essential to un-
derstand the specific profiles of neural and metabolic activity
in any circuit of interest. The combination of BOLD with CBF
and/or CBV measurements as well as with electrophysiology can
help resolve some of these complexities and can deepen our
understanding of the physiological function and pathologies in-
volving the cholinergic system. A better understanding of the
effects of neuromodulators on the BOLD response may improve
the interpretation of fMRI studies such as studies of reward and
attention, etc., where neuromodulation plays a role.
Materials and Methods
Subjects and Ethical Statement.We collected data from eight rhesus monkeys
(Macaca mulatta, seven males and one female), 5–9 y old weighing 8–12 kg.
All experimental procedures were carried out under anesthesia and were
approved by the local authorities (Regierungspräsidium, Tübingen, Ger-
many, Project nos. KY01-07 and KY04-16). Experiments were in full compli-
ance with the guidelines of the European Community for the care and use of
laboratory animals (EUVD 86/609/EEC).
MRI Scanning. We acquired BOLD signals and fCBF using a vertical 4.7 Tesla
Bruker BioSpec scanner with 40-cm-diameter bore (Bruker BioSpin GmbH).
We performed 15 BOLD experiments and 7 CBF experiments. For the BOLD
experiments, we used a custom-built RF surface coil with an inner diameter of
30 mm as transceiver, positioned around the recording chamber. For BOLD
experiments we used an 8-shot Gradient Echo EPI with a field of view (FOV) of
6.4 × 3.2 mm2, slice thickness of 1 mm, an in-plane resolution of 0.25 ×
0.25 mm2, matrix 128 × 256, and receiver bandwidth (BW) 100 kHz. Echo time
(TE) and repetition time (TR) were 18 and 500 ms, respectively, with a flip
angle of 30°. Each experimental session consisted of 592 volumes. To ensure
good homogeneity of the magnetic field, we used FASTMAP to shim over a
volume of 12 mm3 (87) positioned in the area of the electrode tip. For fCBF
measurements, we used a volume coil to transmit in combination with a
custom-built two-channel receive phased array (88). For perfusion imaging, a
flow-sensitive alternating inversion recovery (FAIR) sequence (89) was used
with alternating slice-selective and nonselective inversion pulses (13–15 ms
hyperbolic secant pulse). After an inversion time (TI) of 1,300 ms, a single-slice,
single-shot EPI image was collected. FOV was 64 × 64 mm2, resolution 1 ×
1 mm2, slice thickness 3 mm, receiver BW 100 kHz, and TE/TR 11.5/3,000 ms.
Anatomical reference scans were T2-weighted scans (RARE) with a FOV of 64 ×
64 mm2, slice thickness 1 mm, resolution 0.1 × 0.1 mm2, and TE/TR 46.8/
4,800 ms.
Single-Electrode Neurophysiology. Single-electrode recordings were made
simultaneously with BOLD fMRI. The electrodes were custom-built and
consisted of glass-coated platinum-iridium wires. The tip of the wires was
custom-ground with a 50° angle (3). The amplifiers for the single-electrode
neurophysiology recordings were custom-built and consisted of an analog
compensation mechanism for the noise induced by gradient switching and
RF pulses of the scanner. The details of the methods for interference com-
pensation and signal conditioning are given elsewhere (1, 4, 90). The
interference-compensated signal was then read in by an analog–digital (AD)
converter with 16-bit resolution (National Instruments). The AD converter
was linked directly to a PC running a real-time operating system (QNX). Since
hardware-based gradient noise compensation is incomplete, additional
software-based cleaning of scanner-induced interference was done with
custom-written code based on principal component analysis in MATLAB (The
MathWorks; for details, see refs. 1 and 91).
μECoG Arrays. We custom-designed a μECoG array to record field potentials
from macaque visual cortex (NeuroNexus Technologies, Inc.). The array was
microfabricated on a very thin polyimide film (20 μm) with electrode sites of
50-μm diameter spaced 500 μm apart on a 4 × 8 grid (i.e., 1.5 × 4.0 mm2
rectangular grid). We acutely implanted the μECoG arrays on the surface of
V1. For this, we first performed small skull trepanations (6 mm diameter) using
stereotaxic coordinates in each monkey. Subsequently, we carefully dissected
the meninges layer-wise under the microscope (Zeiss Opmi MDU/S5) to expose
the surface of V1 (Fig. 4A). The injector was attached to a manual microma-
nipulator (Narashige Group), which kept the probe in the desired position
throughout the experiment. We measured the impedance of the electrode
sites before and during the experiments, which ranged from 400 to 600 kΩ.
The signals were amplified and filtered into a band of 1 Hz to 8 kHz using a
multichannel-processor amplifier system (Alpha-Omega Engineering) and then
digitized at 20.833 kHz with a 16-bit resolution ADC converter (National In-
struments). LFPs were extracted by bandpass-filtering the signals and down-
sampling in two steps: (i) first to a sampling rate of 1.5 kHz by using a fourth-
order Butterworth filter (500-Hz cutoff edge); and (ii) to 500 Hz by using a Kaiser
window between 1 and 150 Hz, with a (1-Hz) transition band and stopband at-
tenuation of 60 dB. This two-step procedure was computationally more efficient
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than a single filtering operation to the final sampling rate. The sharp second filter
was used to avoid aliasing, without requiring a higher sampling rate attributable
to a broad filter transition band, which would have increased the computational
cost of all subsequent operations.
Pharmacology. The injectors were custom-designed and consisted of fused-
silica capillary tubing with an inner diameter of 20 μm. For the experiments
that were conducted in the MRI scanner, electrode and injector formed one
unit to assure placement of both at the same depth (the distance from the
injector tip to the electrode was held constant at <1 mm). We used the same
injectors for the μECoG experiments, but here the μECoG array and the injector
were placed independently following dissection of the dura mater.
Before the experiment, we attached the injector to the infusion line that
was directly connected to our pressure-operated injection system (34). This
line was monitored by high-precision flow meters (Sensirion) controlling the
exact applied volume and the actual flow. We used a 1 mM solution of ACh
to induce cholinergic effects in a sufficiently large cortical area to be de-
tectable by fMRI (final injected volume 25 μL). We determined the optimal
concentration and flow rate for our ACh injection by following the time
course of ACh and Ch during the entire experiment using intracortical
sampling of EBF and neurochemistry (for details, see SI Appendix, Fig. S1).
This was done to establish the effects of ACh in the near region while fol-
lowing the effects caused by ACh’s metabolism (21). The concentration that
we used in our current study was optimized to account for the very rapid
conversion of ACh to Ch by AChE. We observed that at a concentration of
1 mM, the level of ACh rapidly increased, followed by an increase in the Ch
level. This was essential in our study, given that a slow and sustained in-
crease in the ACh levels (using lower concentrations) would have led to a
rapid degradation of ACh into Ch in the near region (62, 92). Although the
concentration that we injected in V1 was higher than the physiological
concentrations reported in rodents (0.1–100 μM; ref. 93), the concentration
used in our study was lower than the concentrations used in previous ion-
tophoretic in vivo studies and in vitro studies (15, 68, 94) and was the lowest
concentration that induced changes to the fMRI signals.
We applied the ACh after the fourth repetition of the visual stimulus, and
the injection lasted 8 min (injection period). The pressure-operated injection
system maintained a constant flow during the injection period (34). The ACh
solution was freshly prepared by using ACh-hydrochloride in ACSF. The ACSF
consisted of NaCl (148.19 mM), KCl (3.0 mM), CaCl2 (1.40 mM), MgCl2
(0.80 mM), Na2HPO4 (0.80 mM), and NaH2PO4 (0.20 mM). The pH was ad-
justed with NaOH to 7.25. Finally, drug-free ACSF was used for the control
condition (11). All chemicals were purchased from Sigma-Aldrich (Schnelldorf).
MRI Data Analysis. All data-analysis procedures were implemented in MAT-
LAB. We defined two ROIs that consisted of gray matter in V1, near to (NEAR)
and further from (FAR) the injector: (i) ROINEAR was characterized by the
gray matter surrounding the injector tip and electrode (2 mm diameter); and
(ii) ROIFAR consisted of gray matter further away from the injector (3–5 mm;
Fig. 1B). For each experiment, two sessions were acquired: An 8-min localizer
scan preceding the injection scan was used to identify the voxels showing
reliable visually induced modulation in the Sdefined ROIs (Fig. 1B shows the
NEAR and FAR ROIs). We used a boxcar convolved with a hemodynamic-
response function (γ variant function) as regressor to detect visually induced
modulation. We used this regressor to calculate the correlation coefficient for
every voxel. All voxels showing robust visually induced modulation (P < 0.02)
were used for the pharmaco-based MRI scan. The voxels identified in the
localizer scan were then monitored during the injection scan (39.5 min) and
evaluated for ACh-induced effects. We high-pass-filtered (cutoff frequency
0.0005 Hz) the BOLD and CBF time courses to separate the visually induced
modulation from the baseline changes. The time course of the visually induced
modulation was then calculated by subtracting the image intensity during the
OFF periods from the ON periods and dividing by the OFF period (multiplied by
100 to obtain percent). Baseline changes were computed by taking the image
intensity in each period without visual stimulation and dividing this by the
mean preinjection baseline and converting to a percentage. Mean ACh-induced
changes in baseline andmodulation were calculated during the injection period
(shaded gray area in all figures) and normalized to the preinjection period.
Electrophysiology Data Analysis. To analyze the electrophysiology data, we
used a 1-s nonoverlapping window to calculate the PSD of different fre-
quency bands. We extracted the LFPs and MUA by band-pass filtering the
signals using custom-written MATLAB routines. Forward and backward fil-
tering was used to eliminate phase shifts introduced by the filters. The
boundaries for each frequency band were estimated by quantifying ampli-
tude covariations across LFP frequencies. This procedure involved computing
the signal and noise correlations to distinguish LFP frequencies sharing
common neural properties (for details, see refs. 34 and 95).
To better visualize the power changes due to the pharmacological in-
tervention, we computed the visually inducedmodulation for each frequency
band in the same way as described in MRI Data Analysis. The SNR was
computed as described (10). Briefly, we calculated the SNR as the logarithm
of the power ratio between the signal (during periods with sensory stimu-
lation) and the noise (periods with no sensory stimulation):
SNRdB =10log10

Signal   Power
Noise  Power

,
where the SNR takes changes in amplitude as well as in variability into ac-
count, and thus can be thought of as a measure of coding efficiency (38).
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